Showing results (171-180 of 304) with videos related to
Sort By:
Pageof 31
Oncogene|June 29, 2001
p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elementsP Campomenosi, P Monti, A Aprile, et al.The Journal of Biological Chemistry|July 10, 1983
Isoprene synthesis in isolated embryonic Drosophila cells. I. Sterol-deficient eukaryotic cellsM Silberkang, C M Havel, D S Friend, et al.The Journal of Experimental Medicine|November 14, 2007
Mast cell deficiency in Kit(W-sh) mice does not impair antibody-mediated arthritisJoseph S Zhou, Wei Xing, Daniel S Friend, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 1978
Dietary restrictions early and late: effects on the nephropathy of the NZB X NZW mouseP S Friend, G Fernandes, R A Good, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 20, 1998
Generation of a novel stem cell factor-dependent mast cell progenitorQ Yuan, M F Gurish, D S Friend, et al.The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|May 25, 2001
The presence of v-abl-transformed V3 mast cells in the lungs augments pulmonary vascular permeability to acid aspirationC Mukundan, M F Gurish, K F Austen, et al.Oncogene|August 6, 1999
p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndromeS Quesnel, S Verselis, C Portwine, et al.Oncogene|January 1, 1994
Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancerK W Jolly, D Malkin, E C Douglass, et al.Health Services Research|November 3, 2009
The value of specialty oncology drugsDana P Goldman, Anupam B Jena, Darius N Lakdawalla, et al.Oncogene|March 12, 2008
Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signalingR Tsuchida, B Das, H Yeger, et al.Pageof 31